



September 25, 2023

Nippon Kayaku Co., Ltd.,
Celltrion Healthcare Japan, K.K.,

Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.

Tokyo, Japan, September 25, 2023, Nippon Kayaku Co., Ltd. (Tokyo, Japan, President: Atsuhiko Wakumoto; hereinafter referred to as “Nippon Kayaku”) and Celltrion Healthcare Japan K.K. (Tokyo, Japan, President: Hogun Kim; hereinafter referred to as “Celltrion”) today announced that Nippon Kayaku has been obtained the manufacturing and sales approval of Adalimumab BS Subcutaneous Injection 20mg Syringe 0.2mL·40mg Syringe 0.4mL·80mg Syringe 0.8mL·40mg Pen 0.4mL·80mg Pen 0.8mL “CTNK” (hereinafter referred to as “Adalimumab BS “CTNK”) in Japan.

Adalimumab BS “CTNK” is a biosimilar of the Adalimumab monoclonal antibody that has played an important role in treatment of Rheumatoid Arthritis, Inflammatory Bowel Disease and other autoimmune diseases. Currently approved in 32 countries globally (as of Sep. 2023), including South Korea, EU (European Union) and US.

Nippon Kayaku and Celltrion will make an effort to promote the proper use of this drug, provide information, and ensure a stable supply. In addition, we will promote the domestic development of biosimilars and make an effort to contribute to patients, their families, and medical professionals.

[Please direct inquiries regarding this matter to:]

Telephone: +81-3-6731-5237

Corporate Communications Division

Nippon Kayaku Co., Ltd.

Telephone: +81-3-6260-6840

Celltrion Healthcare Japan, K.K.,